Building the Internet of Bathrooms.

InterVene is a clinical stage medical device company reinventing the way physicians treat severe venous disease in the legs. InterVene's BlueLeaf™ Endovenous Valve Formation System represents the first ever non-implantable, minimally-invasive approach to deep vein valve failure. This technology allows physicians to create new vein valves for severely symptomatic patients with Chronic Venous Insufficiency, an inability to efficiently pump blood out of the legs and back to the heart. Millions of Americans currently suffer from painful venous stasis ulcers (VSU’s) and other costly and devastating symptoms associated with this disease, yet no minimally invasive therapy exists to treat deep vein valve failure, one of the most impactful underlying causes of these symptoms. InterVene plans to change that. After identifying a massive clinical need, I was fortunate to attract a start-up savvy med tech team, and together we invented a first of it's kind endovascular technology and procedure, and executed on a landmark clinical feasibility trial (in pub, Journal of Vascular Surgery, 2021). I am first named inventor on 21 issued InterVene patents, and led fundraising efforts in Seed, Series A and Series B rounds (~$30M total) from angel, venture and corporate sources, to support development of 3 product generations and a series of clinical feasibility studies.

Supporting Development of All Young Children

Biodesign is an interdisciplinary program working to train and create entrepreneurs for the future of Med Tech. A secondary endpoint is the creation of a company or product streaming directly from the program.

The future of epidural catheter delivery

Worked on next generation neurovascular aneurism coils.